KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Assets Average (2016 - 2025)

Historic Assets Average for Xenon Pharmaceuticals (XENE) over the last 12 years, with Q3 2025 value amounting to $641.1 million.

  • Xenon Pharmaceuticals' Assets Average fell 2545.45% to $641.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $641.1 million, marking a year-over-year decrease of 2545.45%. This contributed to the annual value of $881.5 million for FY2024, which is 255.93% up from last year.
  • Xenon Pharmaceuticals' Assets Average amounted to $641.1 million in Q3 2025, which was down 2545.45% from $708.8 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Assets Average high stood at $941.9 million for Q1 2024, and its period low was $239.9 million during Q1 2021.
  • In the last 5 years, Xenon Pharmaceuticals' Assets Average had a median value of $708.8 million in 2025 and averaged $662.7 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Assets Average soared by 19369.3% in 2022 and then tumbled by 2545.45% in 2025.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Assets Average stood at $418.2 million in 2021, then skyrocketed by 82.93% to $765.0 million in 2022, then increased by 6.92% to $817.9 million in 2023, then decreased by 0.11% to $817.0 million in 2024, then dropped by 21.54% to $641.1 million in 2025.
  • Its Assets Average was $641.1 million in Q3 2025, compared to $708.8 million in Q2 2025 and $770.7 million in Q1 2025.